key: cord-0853137-86u73p6g authors: Rampon, Garrett; Jia, Shijing; Agrawal, Ritwick; Arnold, Nicholas; Martín-Quirόs, Alejandro; Fischer, Ernest A.; Malatack, James; Jagan, Nikhil; Sergew, Amen; Case, Amy Hajari; Miller, Kristin; Tanios, Maged; Doros, Gheorghe; Ross, Craig S.; Garcia, Michael A.; Gillmeyer, Kari R.; Griffiths, Nicholas G.; Jandali, Badr; Modzelewski, Katherine L.; Rucci, Justin M.; Simpson, Steven Q.; Walkey, Allan J.; Bosch, Nicholas A. title: Smartphone-guided Self-prone Positioning versus Usual Care in Non-Intubated Hospital Ward Patients with COVID-19: A Pragmatic Randomized Clinical Trial date: 2022-05-18 journal: Chest DOI: 10.1016/j.chest.2022.05.009 sha: 70725c057c344ade71786130659ddba7928d9d64 doc_id: 853137 cord_uid: 86u73p6g Background There is urgent need for safe, effective, and easily implementable treatments that reduce the progression of respiratory failure in COVID-19. Despite increased adoption during the pandemic, the effectiveness of prone positioning on respiratory failure progression among non-intubated patients is unclear. Research Question What is the effectiveness of smartphone-guided self-prone positioning recommendations and instructions compared to usual care to reduce progression of respiratory failure among non-intubated patients with COVID-19? Study Design and Methods APPEX-19 is a multicenter randomized clinical trial that randomized non-intubated adults with COVID-19 on <6 L/minute supplemental oxygen to receive a smartphone-guided self-prone positioning intervention or usual care. The primary outcome was the composite of respiratory deterioration (an increase in supplemental oxygen requirement) or intensive care unit transfer. Using a Bayesian statistical approach, we calculated the posterior probability of superiority within each treatment arm (superiority threshold 95%). Results The trial was stopped early for slow enrollment. A total of 293 participants were included in the modified intention to treat analysis (159 self-prone positioning intervention and 134 usual care). Among participants who self-reported body positioning (n=139; 70 intervention; 69 usual care), 71.4% in the intervention arm and 59.4% in the usual care arm attempted prone positioning. Thirty-one participants (posterior mean 24.7%, 95% credible interval 18.6-31.4%) receiving usual care and 32 participants (posterior mean 22.1%, 95% credible interval 16.6-28.1%) receiving the self-prone positioning intervention experienced the primary outcome; the posterior probability of superiority for the self-prone positioning intervention was 72.1%, less than the 95% threshold for superiority. Adverse events occurred in 26.9% of participants in the usual care arm and 11.9% of participants in the intervention arm. Interpretation Among non-intubated patients with COVID-19, smartphone-guided self-prone positioning recommendations and instructions did not promote strong adherence to prone positioning. older with confirmed or suspected COVID-19 per the treating clinician, were within 48 hours of admission to a medical ward, not intubated and had access to a functioning smartphone during their hospitalization. Patients receiving supplemental oxygen with flow rates of 6 L/minute or more were excluded due to concern from consulting physicians during the design phase and from the institutional review board that self-prone positioning in patients receiving higher oxygen flow rates was rapidly becoming standard care and that clinical equipoise may not exist. Patients were excluded if they had contraindications for prone positioning (e.g., unstable fracture, indwelling chest tube, recent facial trauma or surgery 4 ), were unable to safely self-pronate (e.g., unable to operate the hospital bed or unable to turn from prone to supine without assistance), or had a diagnosis of dementia. Complete inclusion and exclusion criteria are available in e- Table 1 . The trial protocol was approved by the institutional review board at each of the 12 study sites (e- Table 2 ) and was overseen by an independent data and safety monitoring board that reviewed unblinded effectiveness and safety data (e-Appendix 2). Data coordination was provided by the study team at Boston University School of Medicine. All participants provided written informed consent. The study began enrollment on April 25, 2020 and halted enrollment on March 25, 2021 after the study met stopping criteria for low enrollment (one or fewer participants enrolled per week for three consecutive weeks). Participants were allocated to the prone positioning intervention arm or the usual care arm using response adaptive randomization based on the posterior probability of the intervention being superior to usual care. The randomization was initially 1:1 and at each predetermined interim analysis, a beta-binomial conjugate model 9 was employed to update the randomization probabilities to preferentially assign more patients to the better performing study arm. Three of J o u r n a l P r e -p r o o f 9 six planned interim analyses were completed prior to halting the study. Study personnel enrolling patients were blinded to the randomization allocation sequence. Additional details concerning the adaptive randomization are available in the study protocol (e-Appendix 1). Study personnel approached patients for enrollment via in-room hospital telephones, patient cellphones, or as part of entering a hospital room for routine medical care. Participants who enrolled in APPEX-19 received a text message to their personal smartphone containing a link to a Qualtrics-based (Qualtrics XM, Provo, Utah) welcome message customized to their assigned study arm (prone positioning intervention or usual care). The welcome message for participants randomized to the self-prone position intervention arm contained 1) an overview of the potential benefits of prone positioning in COVID-19, 2) a recommendation to lie in the prone position up to 4 times daily for 1-2 hours each session and nightly for a total of 12 hours, 3) pictorial instructions to safely self-prone position while in the hospital, and 4) instructions to keep track of time spent in different body positions while in bed. The welcome message for participants randomized to the usual care arm contained 1) instructions to lie in bed in whichever position was comfortable, and 2) instructions to keep track of time spent in different body positions while in bed. All participants were then sent separate monitoring survey links twice daily via text messages that contained the initial treatment arm instructions (including a reminder to prone position in the intervention arm) and prompts to report complications and estimates of time spent in different positions. Surveys were sent until any of the following occurred: the primary outcome was reached, the participant was discharged from the hospital, or 14 days had passed since enrollment. Intervention adherence was assessed by participant self-report on twice daily surveys. An amendment to the study protocol (eAppendix 1) allowed remote contact of J o u r n a l P r e -p r o o f 10 participants who had not responded to a survey in 24 hours to troubleshoot technical issues and to remind participants to complete surveys. Screenshots of the treatment arm smartphone messages and surveys are included in e- Figure 1 . There were no restrictions to prone positioning in the usual care group (neither participants nor providers were advised against prone positioning) and clinical staff were blinded to treatment assignment. Study investigators selected a smartphone-based approach to avoid the need for study staff to enter patient rooms, because of prior reported success of smartphone-based interventions 10, 11 to change behavior, and because smartphones have been widely adopted across demographic and socioeconomic groups 12 making them widely implementable. Participant study materials were developed iteratively by the study investigators including experts in ecological momentary assessment (CSR) and implementation (AJW) and were translated to Spanish by certified medical translators. Electronic medical record data, including outcome data, were collected at enrollment and daily thereafter by study personnel and were entered into centralized Research Electronic Data CAPture and Qualtrics databases. 13, 14 Participants recorded prone position adherence information, adverse events, and their level of dyspnea on twice daily electronic surveys. The primary outcome, specified to assess the effectiveness of self-prone positioning on reducing the progression of acute respiratory failure, was the composite of (1) respiratory deterioration or (2) transfer to the ICU. Respiratory deterioration was defined as an increase in the supplemental oxygen flow rate of >2 L/minute compared to the flow rate at the time of the initial welcome text message and sustained for >12 hours, or a switch to a higher level of oxygen support (e.g., a transition from nasal cannula to non-rebreather mask, high flow nasal cannula, J o u r n a l P r e -p r o o f 11 non-invasive positive pressure ventilation, or mechanical ventilation). Secondary effectiveness outcomes included each individual component of the primary composite outcome, receipt of mechanical ventilation, hospital mortality, diagnosis of ARDS, and each participant's median self-reported level of dyspnea as measured by the modified Borg dyspnea scale. 15, 16 Secondary safety outcomes were the self-reported degree of discomfort with self-prone positioning, and loss of venous or urinary catheters, captured through survey prompts (e- Figure 1 ). Prone positioning adherence was recorded for time categories of no time, up to 6 hours, 6-11 hours, and 12 or more hours since the last monitoring survey. Outcome data collection was collected until the participant was discharged from the hospital or 14 days after enrollment, whichever came first. Based on preliminary data at Boston Medical Center from Spring 2020, we determined a maximum total of 560 participants would have 90% power to reject the null hypothesis, assuming a primary outcome rate of 24.5% in the self-prone positioning arm and 35.0% in the usual care arm. In the primary analysis, we used a modified intention-to-treat approachincluding all participants who were randomized and subsequently received the initial welcome text message instructions prior to discharge from the hospital, transfer to the ICU, or study withdrawal. We used Bayesian analyses to calculate the posterior probability: the probability of the primary outcome accounting for the probability prior to randomization and the data gathered from the study. A priori, we selected a prior probability [Beta (12+events, 28+non-events)] that assumed the effects of the prone positioning intervention in our cohort would be small. This prior has a mean of 30% (average of assumed rates) and was selected to express apriori skepticism of the alternative hypothesis being true; indeed, under this prior, the prior probability of the alternative hypothesis is 50%, while the probability of observing an improvement in the true rate of 10.5% or larger (the hypothesized improvement) is only 15%. Thus, only strong study data supporting the use of self-prone positioning would be taken as evidence that self-prone positioning was superior to usual care. For each treatment arm, we reported the posterior mean (the posterior probability distribution average for the primary outcome) and 95% credible interval. We pre-defined that self-prone positioning would be considered superior to usual care if the data showed that there was a greater than 95% probability that the posterior probability in the intervention arm was less than that of the usual care arm. Unlike the p-value, the posterior probability for superiority provides the probability of the alternative hypothesis being true (i.e., that the intervention is superior to usual care), and thus may be informative even when below the pre-defined superiority threshold of 95%. Additional details of the Bayesian approach are in the statistical methods (e-Appendix 1, pages [16] [17] [18] . In addition to the intention to treat analysis, we performed an exploratory analysis that compared participants in the intervention arm who self-reported prone-positioning for 6 or more hours at least once to participants in the usual care arm who did not self-report prone positioning on any survey. The single 6-hour prone positioning duration for inclusion in the exploratory analysis was selected due to the improvement in oxygenation using this duration in a prior prone positioning clinical trial 17 and the concern from study investigators that longer durations used for mechanically ventilated patients with ARDS 4 would not be feasible in non-intubated patients. We were unable to adjust for a priori selected covariates in the exploratory analysis given the low number of outcomes. J o u r n a l P r e -p r o o f 13 Prespecified subgroups tested for heterogeneity of treatment effect were (1) enrollment body mass index <30 kg/m 2 vs. ≥30 kg/m 2 , (2) enrollment age <65 years vs. ≥65 years, (3) no history of congestive heart failure vs. history of congestive heart failure, (4) no receipt of oxygen at the time of enrollment vs. receipt of oxygen at the time of enrollment, (5) no opacities or infiltrates on admission chest x-ray vs. opacities or infiltrates on admission chest x-ray, and (6) negative or pending vs. positive SARS-CoV-2 test result at the time of enrollment. Dichotomous secondary effectiveness outcomes were compared using risk differences with 95% confidence intervals. Continuous secondary effectiveness outcomes were presented as medians and interquartile ranges for each treatment arm. No corrections for multiple testing were made for the exploratory analysis, subgroup, or secondary outcomes. Adverse events were reported as the number of participants and associated percentages that experienced at least one adverse event per treatment arm. The complete statistical analysis plan is included in study protocol (e-Appendix 1). R (version 4.0.5) was used for analyses. From April 25, 2020 to March 25, 2021, 3128 patients were screened, 305 participants underwent randomization, and 293 participants (134 in the usual care arm, and 159 in the selfprone positioning intervention arm) were included in the modified intention to treat analysis ( Figure 1 ). Participants were on average 53 (IQR 41-63) years old, had COVID-19 symptoms for 7 days (IQR 4-10) prior to hospital admission (Table 1) reported lying in the prone position at least once and 25 (35.7%) reported lying in the prone position for 6 or more hours at least once. In the usual care arm, 41 (59.4%) reported lying in the prone position at least once and 9 (13.0%) reported lying in the prone position for 6 or more hours at least once. In total, among those who received their initial treatment assignment, 25 participants in the self-prone positioning intervention arm documented prone positioning and 60 participants in the usual care arm documented not positioning themselves in the prone position and thus were included in the exploratory analysis. The self-reported time spent in the self-prone position by treatment arm and survey is shown in e- Table 3 . The primary outcome of respiratory deterioration of ICU transfer was experienced by 31 participants (posterior mean 24.7%, 95% credible interval 18.6-31.4%) in the usual care arm and 32 participants (posterior mean 22.1%, 95% credible interval 16.6-28.1%) in the self-prone positioning intervention arm (posterior mean difference -2.6%, 95% credible interval -11.2%, 6.0%). The posterior probability of superiority for the self-prone positioning intervention was J o u r n a l P r e -p r o o f 15 72.1%, less than the 95% pre-specified threshold for superiority ( Table 2 ). The posterior probability of inferiority of the self-prone positioning intervention was 10.0%, also less than the 95% pre-specified threshold for inferiority. Characteristics of patients (n=85) included in the exploratory analysis are shown in e- Table 4 . In the exploratory analysis comparing participants who reported self-prone positioning in the intervention arm to participants who did not selfprone position in the usual care arm, the primary outcome occurred in 1 participant in the self- (Table 2) . There were no differences between the self-prone positioning intervention arm and the usual care arm across all secondary effectiveness outcomes (Table 3) . Participants' respiratory parameters over time are shown in e- Figure 2 . Adverse events occurred in 19 (11.9%) participants in the self-prone positioning intervention arm and 36 (26.9%) participants in the usual care arm. Fourteen (8.8%) participants in the self-prone positioning intervention arm and 28 (20.9%) in the usual care arm reported being very uncomfortable with self-prone positioning. Nine (5.7%) participants in the self-prone positioning intervention arm and 12 (9.0%) in the usual care arm reported loss of an intravenous catheter and 1 (0.6%) and 0 (0.0%) reported loss of a urinary catheter in the intervention and usual care arms, respectively. There were no serious adverse events. In this multicenter, unblinded, randomized clinical trial, smartphone-guided self-prone positioning recommendations and instructions did not promote strong adherence to self-prone positioning. Notably, the study was terminated prematurely due to low enrollment, fewer than two thirds of participants accessed their treatment assignment on their smartphones, and the selfreported time spent in the prone position was short. Thus, the study was underpowered to make conclusions concerning the effectiveness of self-prone positioning recommendations and instructions or self-prone positioning itself in reducing clinical deterioration. Our study highlights three important aspects of self-prone positioning for non-ICU, nonintubated, hospitalized patients during the COVID-19 pandemic. First, smartphone-guided delivery of trial instructions among hospitalized patients with COVID-19 had low rates of adherence. Only 60% of participants accessed their randomization group, and fewer than 40% reported self-prone positioning for 6 or more hours, suggesting participant difficulty with both accessing and adhering to the smartphone-guided interventions. Thus, time spent in the prone position in our study was substantially shorter in duration compared to a recent meta-trial 5 among critically ill patients with COVID-19 on high flow nasal cannula that found prone positioning reduced rates of treatment failure. Importantly, the meta-trial intervention used assisted prone positioning. In contrast, clinical trials 18 including ours, that included recommendations for self-prone positioning but no direct assistance, have had shorter durations and lower adherence to prone positioning. These results suggest that the efficacy of prone positioning in non-intubated patients may strongly depend on the degree to which staff assist with the maneuver. In contrast to our findings of low adherence, studies of smartphone-based interventions for chronic disease management 10, 11 have reported high rates of adherence. We speculate that the low adherence and low access rate in our study was due in part to inclusion of hospitalized patients with acute illness who may be less able or motivated to navigate their smartphones compared to outpatients. It is also possible that the specific smartphone-guided recommendations and instructions in our study were ineffective, and the low rate of adherence may not be generalizable to other smartphone-guided interventions in the inpatient setting. Further research is required prior to more widespread use of smartphone-guided intervention delivery for hospitalized patients. Second, among patients who did self-prone position for six or more hours, outcomes may be favorable. In our study, participants who self-prone positioned in the intervention arm showed a 90% posterior probability for superiority in reducing the rate of respiratory deterioration and ICU transfer as compared with participants who did not self-prone position in the usual care arm. However, this exploratory analysis may be confounded by a strong association between post-randomization factors that predict adherence (e.g., patient ability to access their smartphones and perform self-pronation) and outcome. 19 Third, self-prone positioning among non-intubated, hospitalized patients who received instructions via smartphone was generally well tolerated and without serious side effects. Our study has several limitations. First, the study was terminated for low enrollment. Thus, whether completion of the study to the planned sample size would lead to different results is unknown. Second, only about two-thirds of participants opened the smartphone-guided survey containing their treatment assignment and just under half self-reported their time spent in the prone position. Thus, it is unclear if our primary findings of no difference were driven by lack of effectiveness of prone positioning in the study population, lack of effectiveness of the smartphone-guided delivery platform and instructions, not reaching the planned sample size, and/or the short duration spent in the prone position. Nineteen percent of approached patients declined to participate and patients who were unable to self-prone position were excluded. Thus, the external validity of our results may be limited. A small percentage of participants (<10%) did not have a positive SARS-CoV-2 test at the time of enrollment. The effect of these patients with suspected COVID-19 on study outcomes, and the ultimate status of subsequent tests is unknown. Lastly, the inclusion of patients receiving <6 L/minute via nasal cannula was necessitated by concern that clinical equipoise may not exist for patients on higher flow rates of oxygen. However, prone positioning may be more beneficial in patients with severe respiratory disease 20 . Thus, the lack of effectiveness of our study may be due to the lower severity of respiratory disease included in the study cohort. Among non-intubated, non-ICU hospitalized patients with COVID-19, smartphone- Results: Among 293 participants, the posterior probability of superiority for the self-prone positioning intervention compared to usual care was 72.1%, below the pre-defined superiority margin; however, the study was stopped early due to low enrollment. Interpretation: Among non-intubated, non-ICU hospitalized patients with COVID-19, smartphone-guided self-prone positioning recommendations and instructions did not promote strong adherence to prone positioning. Prone positioning is the positioning of the body so that the stomach and chest are facing down flat towards the bed. Prone positioning in ARDS has been studied for many years, with the latest data suggesting benefit in patients with severe ARDS (defined as a PaO2/FiO2 <150) who are mechanically ventilated. Patients "proned" for >16 hours a day showed an improvement in mortality at 28 days. Pathologically, alveolar consolidation is not uniform throughout all regions of the lung. The benefit of prone positioning appears to be due to improved ventilation/perfusion matching and recruitment of previously atelectatic/collapsed regions of dependent lung. In most ICUs, it is standard of care to use prone positioning in mechanically ventilated patients with ARDS and a PaO2/FiO2 <150, including those with COVID-19. To our knowledge, there are no randomized trials that address the physiologic benefits of prone positioning in non-intubated, non-critically ill patients including those under evaluation for COVID-19. A retrospective cohort study of 15 ARDS patients utilizing NIV showed feasibility of prone positioning in the awake patient without adverse events. A separate case series of non-intubated awake patients with COVID-19 from China reported improved oxygenation with the use of prone position. Here, we aim to study the effect on respiratory deterioration and ICU transfer of intermittent prone positioning in non-intubated patients with COVID-19 or who are under evaluation for COVID-19. This is an important and unanswered question, especially in light of our current lack of evidence-based treatments for COVID-19 and the need to limit transfer to over-crowded ICUs. This study will be conducted in compliance with the protocol, applicable regulatory requirements, and BMC/BU Medical Campus Human Research Protection policies and procedures. As detailed above, prone positioning is a well-studied and validated treatment for severe ARDS, however there are no randomized studies on the use of prone positioning in the non-intubated patient. The purpose of this trial is to investigate the use of prone positioning in SARS-CoV-2 infected patients who are not intubated. It is unknown if this intervention would be helpful in preventing further deterioration in terms of hypoxemia and ICU admission. The primary outcome in this study is a composite outcome for respiratory deterioration defined as at least one of the following: 1) ICU transfer 2) an increase in supplemental oxygen delivery (defined as an increase in oxygen delivery rate of ≥2 liter per minute compared to the oxygen delivery rate at the time of the first intervention or usual care text message that is sustained for ≥12 hours OR the switch to an oxygen delivery method that increases the level of supplemental oxygen [nasal cannula and shovel mask < nasal pendant < Venturi mask < Nonrebreather < HFNC < CPAP or BPAP]). The time of the primary outcome will be defined as either the time of ICU admission or the time when the increase in supplemental oxygen delivery first occurred. Secondary outcome measures for this study include: The APPEX-19 Study is a multicenter pragmatic adaptive randomized controlled unblinded trial. APPEX-19 compares hospitalized patients with COVID-19, or who are under evaluation for COVID-19, who receive a recommendation to lie in a prone position (i.e. with their stomach and chest facing flat towards the bed) to usual care. A total of up to 560 subjects will be randomized using response adaptive randomization based on the posterior probability of the active treatment (Treatment A) being superior to the usual care (Treatment C) treatment. The trial is designed to assess the superiority of treatment A compared to standard of care (treatment C) with respect to the primary endpoint. A Bayesian approach using a Beta-Binomial conjugate model is employed to (1) formally assess the superiority of Treatment A to Treatment C, and (2) to adaptively change the randomization ratio to favor the treatment arm favored by the data collected. Enrollment will begin on 4/2020 and continue until 8/2021 We will include adult patients who are admitted or who will be admitted to a participating study site medical wards (not ICU), who have COVID-19 or who are under evaluation for COVID-19, who are English or Spanish-speaking, who have the ability to read simple instructions and answer simple written questions, and who have access to a functioning smartphone in the hospital room. Exclusion criteria are outlined in the study selection section. We have chosen a pragmatic randomized controlled unblinded trial for two primary reasons: 1) The intervention involves having a patient lie on their stomach, a procedure that cannot be blinded to the clinician or study participant, 2) given the severity of the current COVID-19 pandemic and resulting scarcity of resources, we thought that a pragmatic adaptive study design would allow rapid testing of the effectiveness of prone positioning in non-intubated COVID-19 patients and ensure that the most number of patients will receive the treatment that is most effective. It is expected that sites' procedures will differ based on local policies and best practices and the consent form and process will be approved by each site's IRB. Informed consent will be conducted in accordance with the regulations for Protection of Human Subjects at 45 CFR 46.116 and 45 CFR 46.117. A template consent form containing all the required elements of consent will be provided to each site. Patients are assigned to one of two treatment arms using an adaptive randomized schema. Initially, the randomization will be balanced, then as data are accrued, assignment probabilities will be shifted in favor of arm that is performing better. The first 140 subjects will be assigned using equal allocation (1:1) to both study arms (A = Active and C = Usual Care). Then, we will compute the probability that the Event Rate in Group A is smaller than the Event Rate in Group C. Thereafter, the value of will determine the random assignments to treatment. In particular, the assignment to treatment A will be proportional to , more precisely, The update for the value of will occur every time the dataset with outcome data is updated, but for logistical simplicity the update will be performed after every 70 subjects enrolled. No concealment or blinding will be used in this study. Participants, study personnel, and clinicians will be aware of treatment assignments. Study participants in the intervention arm will receive an initial text message (see the schedule of events appendix for the text messaging language) on their smartphones linking to the Qualtrics intervention website. The Qualtrics intervention website will include the following sections: 1) Welcome message 2) Brief educational review of the potential benefits of prone positioning 3) How-To guide to safely "prone" in a hospital bed 4) A recommendation to "prone" while lying in bed (up to 4 times daily for 1-2 hours each time and at night for up to 9 hours) 5) A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking Study participants in the intervention arm will also receive a reminder recommendation to "prone" (number 4 above) with an option to review the How-To guide to safely "prone" in a hospital bed (number 3 above) with twice daily Qualtrics monitoring surveys. Study participants in the usual care arm will receive a text message (see the schedule of events appendix for the text messaging language) on their smartphone linking to the Qualtrics usual care website. The Qualtrics usual care website will include the following sections: 1) Welcome message 2) A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking We will use Qualtrics to conduct real-time brief monitoring surveys of participants to collect compliance, efficacy, and safety outcome information at two time points during each 24-hour period (10AM and 7PM). The monitoring survey for the intervention arm will also contain a reminder recommendation to "prone" and an option to review the How-To guide to safely "prone" in a hospital bed. The monitoring surveys will be created and maintained by the Boston University study team using Qualtrics Software. However, each institution will be responsible for sending out text messages to their site-specific participants including a link to each Qualtrics survey. Thus, each site will maintain their own list of participant smartphone numbers linked to study IDs. The Qualtrics survey data maintained by the coordinating center will not contain any direct identifiers. In addition to the monitoring surveys, we will collect baseline clinical data on enrollment and data for determination of the primary outcome and secondary outcomes by daily review of routine information collected from the EMR at each institution. J o u r n a l P r e -p r o o f 8 The EMR information from each institution will be entered into a centralized REDCap database maintained by Boston University that will include dates, but no direct identifiers. For Boston Medical Center participants only, the REDCap database will additionally include smartphone numbers. Prone positioning is an intervention that can be completed safely in critically ill, mechanically ventilated, bed-bound patients with appropriate planning and personnel support 3 . Specific contraindications to prone positioning in critically ill, mechanically ventilated, bed-bound patients are exclusion criteria to this study. In prior trials of prone positioning in a critically ill mechanically ventilated population, proposed risks were related to possible removal of tubes or lines, endotracheal tube dislodgement, as well as development of pressure ulcers. However, no increased risk of these outcomes was found 3 . In our population of non-critically ill participants who will not be bed-bound and who will be able to turn themselves from lying on their backs to their stomach, the potential risks will be lower. Specifically, there is no endotracheal tube that could be dislodged, and since awake participants have the ability to shift their position, they should not be at risk for pressure ulcer development. Potential risks include: 1) Discomfort while lying in the prone position: the magnitude of this risk is minimal as participants may freely return to a non-prone position to relieve their discomfort. The probability of occurrence is moderate and likely will be related to the duration spent in the prone position. The potential duration of this risk is very short, as returning to a non-prone position should resolve discomfort. 2) Dislodgement of an IV catheter or urinary catheter: the magnitude of this risk is minimal. IV and urinary catheter function and placement is assessed as part of routine care by nurses. Any dislodgement would thus be rapidly identified and rectified. In addition, IV catheters are inserted into a low-flow vein, and thus dislodgement is unlikely to cause significant bleeding. Urinary catheters have connecting tubes that allow for slack with independent movement and walking. The probability of occurrence is low as IV catheters are secured into position with Tegaderm tape and urinary catheters are secured via an inflatable balloon. We will also recommend to participants that they are careful to avoid dislodgement during repositioning in bed. The potential duration of catheter dislodgement is up to 4 hours (the duration between nursing assessments) but should be shorter in most cases as the participant can use the call button on their bed to request assistance sooner. The risk of discomfort in the prone position will be minimized by excluding patients who are not able to independently return to lying on their backs from the prone position. In addition, we will provide a How-To guide to safely self-prone position including images that suggest positions to minimize discomfort. The risk of catheter dislodgement will be minimized by recommending to participants how to avoid dislodgement catheters during the self-prone position process. Individual Benefits: Prone positioning is known to improve oxygenation and reduce mortality in patients who are mechanically ventilated with moderate to severe ARDS and is the standard of care in ICUs in this critically ill population, including those critically ill with COVID-19. It is possible that in patients with COVID-19, prone positioning early in the disease course, when patients are less severely ill, could reduce supplemental oxygen requirements, prevent ICU transfer, or decrease the need for intubation. The COVID-19 pandemic is a global phenomenon and continues to spread in the United States and internationally. In addition to the individual morbidity and mortality caused by the J o u r n a l P r e -p r o o f 9 virus, it is creating unprecedented strain on hospital resources, particularly in the ICU. By identifying interventions that reduce the number of patients requiring ICU resources and that can be implemented with low cost and minimal staff involvement, we can optimize the limited resources available for treating COVID-19 patients during the pandemic. The risks to participants are minimal, and the potential individual and societal benefits are great. Taken together, we believe the potential benefits of this study far outweigh the risks of intermittent prone positioning. In order to be eligible to participate in this study, an individual must meet all the following criteria: -Adult patient (> 18 years old) -Admission to the medical wards or planned admission to the medical wards from the ED within the previous 48 hours (not ICU) -confirmed COVID-19 infection or under evaluation for COVID-19 -Have access to their own functioning smartphone that can connect to the internet and receive text messages in the hospital room -English or Spanish-speaking -Ability to read simple instructions and answer simple written questions An individual who meets any of the following criteria will be excluded from participation in this study: Baseline patient factors -Inability to operate the hospital bed -Inability to lie flat comfortably -Inability to lie flat without shortness of breath -Inability to turn over independently Medical comorbidities -Hemoptysis in the last 2 days -Prior lung transplant -Dementia Acute issues -Deep venous thrombosis treated for less than 2 days -Unstable spine, femur, or pelvic fractures -Mean arterial pressure lower than 65 mmHg -Receiving ≥6 liters per minute of supplemental oxygen via nasal cannula, nasal pendant, or shovel mask -Receiving supplemental oxygen via Venturi mask or non-rebreather mask Study participants in the intervention arm will receive a text message (see the schedule of events appendix for the text messaging language) on their smartphones linking to the Qualtrics intervention website. The Qualtrics intervention website will include the following sections: 1) Welcome message 2) Brief educational review of the potential benefits of prone positioning 3) How-To guide to safely "prone" in a hospital bed 4) A recommendation to "prone" while lying in bed (up to 4 times daily for 1-2 hours each time and at night for up to 9 hours) 5) A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking Study participants in the intervention arm will also receive a reminder recommendation to "prone" (number 4 above) with an option to review the How-To guide to safely "prone" in a hospital bed (number 3 above) with twice daily monitoring surveys Usual Care Arm Study participants in the usual care arm will receive a text message (see the schedule of events appendix for the text messaging language) on their smartphone linking to the Qualtrics usual care website. The Qualtrics usual care website will include the following sections: 1) Welcome message 2) A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking Specific study procedures in relation to recruitment, screening and consent may vary by site. However, all inclusion/exclusion criteria, interventions, monitoring surveys, and data collection from the EMR will be the same across sites. In addition, any protocol updates will be sent to each site PI for signature and for IRB submission/approval. A copy of the version updates with each site PI's signature will be returned to the Boston University study team. The Boston University study team will thus ensure that updates to the protocol version are verified at all other sites such that all sites are following the same protocol version. Study participants will be enrolled from 4/2020 and continue until 8/2021. We expect the total study duration from the beginning of enrollment to completion of data analysis to be from 4/2020 to 11/2021. Study participation duration will continue from the time of enrollment to the time when the primary outcome is reached, hospital discharge, hospital death, or 14 days have passed since enrollment, whichever comes first. Remote routine EMR data will continue to be collected after the primary outcome is reached to determine secondary outcomes. The recruitment and prescreening procedures may vary by institution and will be approved by each site's IRB. The recruitment and screening processes at BMC are outlined in the schedule of events. The screening procedures may vary by institution and will be approved by each site's IRB. The recruitment and screening processes at BMC are outlined in the schedule of events. The consent procedures may vary by institution and will be approved by each site's IRB. Copies of the IRB approved site-specific consent procedures will be maintained by the Boston University study team. The signed and dated consent forms for each study site will be kept locally according to the processes approved by each site's IRB. It is expected that sites' procedures will differ based on local policies and best practices and the consent form and process will be approved by each site's IRB. Although each site will develop its own procedures specific to institutional local best practices, a remote consent process is encouraged. This may be accomplished in two ways: 1) Using an electronic consent form, where the researcher will conduct the consent discussion over the phone with the subject who will view and sign the electronic consent form on his/her own device. The researcher will electronically sign the same form. In this case, a witness will not be required. The subject/LAR will receive an electronic copy of the signed form 2) Using a hardcopy form, where the researcher and subject have their own copies of the consent document and the consent discussion happens over the phone. The form signed by the subject will be kept by the subject and the form signed by the researcher will be kept by the researcher. In this case, a witness signature will be required, attesting to signing on behalf of the subject and at the direction of the subject. The witness must be an adult and separate from the study team. If approved by site-specific IRBs, sites may also consent participants directly in-person with physical signatures by the participant and researcher. The study will also enroll Spanish speakers. The full consent form will be translated to Spanish. The consent process will be conducted by a member of the study team who is fluent in Spanish or with a member of the study team along with a Spanish interpreter who will translate the discussion. Each individual site will be responsible for permanently deleting all PHI and sensitive information for potential participants who did not enroll (because of screening out or because they declined to participate at any step in the pre-screen, recruitment, screening, and consent processes). PHI and sensitive information will be deleted within 24 hours except for the MRN which will be retained so that they are not approached again. Each site will retain a tally of the number of potential participants who declined to participate and a tally of the number of potential participants who screen fail due to each inclusion/exclusion criteria. separately send a text (see appendix for wording) to the participants at their specific study sites containing a link to the intervention or usual care Qualtrics website administered by the Boston University study team. The intervention and usual care Qualtrics websites will be the same across all sites except for site-specific contact information. The app used by each study site to send text messages will be approved by the site-specific IRB. Participants who were consented between 8AM and 12PM local time will receive their initial text messages anytime up until 7PM local time and participants consented between 12PM and 8AM local time will receive their initial text messages anytime up until 10AM local time. APPEX-19 investigators will not seek to dictate or overrule the recommendations that are provided by participants' clinicians in regards to bed positioning. At BMC, the text will be sent by research staff using the "DO IT LATER" app on a research mobile phone protected with a pin number. The participant will only receive a text message via SMS and will not interact with the "DO IT LATER" app, which is only used to schedule the transmission of text messages. At all study sites, each participant will receive automatic text messages via their smartphones (using site-specific IRB approved text messaging apps) with links to the Qualtrics monitoring surveys at 10AM and at 7PM local time everyday starting after the initial intervention or usual care text has been sent. Monitoring surveys will continue to be sent until the primary outcome is met, the participant is discharged from the hospital, the participant dies, or 14 days have passed since enrollment. The survey will contain 5 components: (1) estimated length of time spent in lying flat on stomach, lying flat on back, lying on side, sitting up, and standing or walking, (2) level of dyspnea as measured by the validated modified Borg Dyspnea Score, and (3) discomfort with lying flat on stomach (for the intervention group) or discomfort lying in each of the bed positions (for the usual care group) on a 4-point ordinal scale, (4) a query about dislodgement of IV catheter during repositioning in bed, and (5) a query about dislodgement of urinary catheters during repositioning in bed. For the intervention monitoring survey, study participants will also receive a reminder recommendation to "prone" with an option to review the How-To guide to safely "prone" in a hospital bed. Participants who do not complete the monitoring survey within 60 minutes of receiving the text message will receive a single reminder text and monitoring survey link after each incomplete survey. The monitoring surveys will be the same across all sites except for site-specific contact information. Survey links are not password protected but once clicked, do not provide any results from previous or current surveys (just a blank survey form is generated). Thus, there is no loss of confidentiality in the event that someone other than the participant clicks on the survey link. All surveys across sites are generated by the Qualtrics software administered by Boston University. At BMC, the survey text messages and links are generated by the "DO IT LATER" application and sent directly to each participant's smartphone. At all study sites, routine EMR data will be extracted at the time of enrollment and daily thereafter until the time of discharge or 14 days have passed since enrollment, whichever comes first. No additional data will be collected using procedures that are not part of routine care. The list of EMR data that will be extracted is included in the schedule of events in the appendix and will be collected by study team personnel at each study site into the REDCap database administered by the Boston University study team. The following definitions will be used in the assessment of safety: Adverse Event (AE) is defined as dislodgement of an IV or urinary catheter or participant report of being very uncomfortable with prone positioning. (1) results in death; (2) is life-threatening; (3) results in inpatient hospitalization or prolongation of existing hospitalization; (4) results in a persistent or significant disability/incapacity; (5) results in a congenital anomaly/birth defect; or (6) based upon appropriate medical judgment, may jeopardize the subject's health and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition (examples of such events include allergic bronchospasm requiring intensive treatment in the emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse). Life-threatening means that the event places the subject at immediate risk of death from the event as it occurred. Unanticipated Problem is defined as an event, experience or outcome that meets all three of the following criteria: • is unexpected; AND • is related or possibly related to participation in the research; AND • suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized. Possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research Unexpected means the nature, severity, or frequency of the event is not consistent with either: • the known or foreseeable risk of adverse events associated with the procedures involved in the research that are described in (a) the protocol-related documents, such as the IRB-approved research protocol, any applicable investigator brochure, and the current IRB-approved informed consent document, and (b) other relevant sources of information, such as product labeling and package inserts; or • the expected natural progression of any underlying disease, disorder, or condition of the subject(s) experiencing the adverse event and the subject's predisposing risk factor profile for the adverse event. Both the risks listed in Section 6.1 and unknown risks will be monitored as follows: Adverse events including loss of IV or urinary catheter and discomfort in the prone position will be monitored by study personnel through the use of the twice daily surveys. In addition, all study outcomes will be reviewed by the study team. Adverse events and outcomes will be submitted every 7 days to a safety monitoring team consisting of 2 independent pulmonary physicians at BMC (Drs. Hasmeena Kathuria and Arthur Theodore) and a statistician (Dr. Robert Lew). As Boston University is administering the Qualtrics and REDCap platforms through which all outcome and safety data will be collected, the Boston University study team will be able to report adverse events, outcome, data and other required information across study sites to the independent safety monitoring team in a responsive manner. Qualtrics and REDCap data from each site will be updated and transmitted at least daily to the coordinating center. Unanticipated problems that are not included in the Qualtrics or REDCap platforms will be communicated to the BU PI within 24 hours of the event occurring who will then send to the independent safety monitoring within 24 hours of receipt. The independent safety monitoring team will evaluate any known adverse events and review outcomes for major differences between the intervention and usual care group. The independent safety monitoring team will send their written report back to the BU PI within 48 hours of receiving/reviewing the adverse event and outcome information. The BU PI will communicate safety concerns to the site PIs within 48 hours of receipt. If there are no safety concerns, the BU PI will communicate such to the site PIs within 72 hours of receipt. Each site should report this information to its IRB per local requirements. At BU, any safety concerns identified by the monitors will be reported to the IRB within 7 days of being aware of the event; otherwise, the monitors' report will be submitted to the IRB at the time of the continuing review. Site Principal Investigators will report Unanticipated Problems, safety monitors' reports, and Adverse Events to their local IRBs in accordance with IRB policies: • Unanticipated Problems occurring at BMC/BU Medical Campus will be reported to the IRB within 7 days of the investigator learning of the event. • Reports from safety monitors with recommended changes will be reported to the IRB within 7 days of the investigator receiving the report. • Adverse Events (including Serious Adverse Events) will be reported in summary at the time of continuing review, along with a statement that the pattern of adverse events, in total, does not suggest that the research places subjects or others at a greater risk of harm than was previously known. • Reports from safety monitors with no recommended changes will be reported to the IRB at the time of continuing review. We set two parameters and that govern how to stop the experiment either for overwhelming superiority or overwhelming futility: These two parameters are chosen so that the Type I error is <10%. We calculated the maximum value for the total accrual of 560 subjects, based on a standard power calculation inflated as needed to preserve adequate power under clinically important differences. In addition, the study may be stopped based on low enrollment, such that it is no longer feasible to continue the study. The rate of enrollment at which the study may be stopped is 1 participant or less per week for three consecutive weeks. 10 Data Handling and Record Keeping 10.1 Confidentiality All data that includes subject identifiers will be stored and analyzed using HIPAA-compliant electronic systems (REDCap) administered by the Boston University study team that meet standards for protection of identifiable data established by BMC and the BUMC IRB. A master code linking patient MRNs with their study identification numbers will be kept in a password protected file on a secure BMC server (BMC Box) for BMC participants. For participants at other study sites, the master code linking patient MRNs with their study identification numbers will be kept in a password protected file on a site-specific server approved by each site's local IRB. Each study site will also maintain a password-protected list linking study IDs to smartphone numbers. At BMC, smartphone numbers will be kept in the HIPAAcompliant electronic system REDCap. No smartphone numbers or other direct identifiers for non-BMC sites will be kept in the REDCap database administered by Boston University. All patient identifiers linked to the data will be destroyed at the end of the seven-year holding period required by BMC including the master code. The study will be registered on clinicaltrials.gov and will be updated as necessary by the study team. The independent safety monitor may inspect all documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the subjects in this study. The clinical study sites will permit access to such records. Data will be extracted from hospital charts via the EMR. Additional data will be gathered from the participating subject's twice daily Qualtrics monitoring surveys administered by the Boston University study team. REDCap database software administered by the Boston University study team will be the primary data collection instrument for manually extracted data by the sites. All data will be collected using REDCap and Qualtrics software including screening data. No hardcopy case report form will be used in this study. All patient data obtained for this study will be preserved electronically on HIPAA-compliant electronic systems for at least seven years after the study is completed. All documentation of informed consent of subjects will be retained for at least seven years after completion of the study. All hardcopy documentation will be stored in a locked filing cabinet in each study sites PI's office. 11 Statistical Plan 11.1 Study Hypotheses J o u r n a l P r e -p r o o f 16 We hypothesize that patients who receive a smartphone-based recommendation to initiate self-prone positioning in spontaneously breathing, non-intubated patients hospitalized with COVID-19 or under evaluation for COVID-19 will have a lower incidence of respiratory deterioration (as determined by our composite primary outcome) compared to patients who receive usual care. The null hypothesis is that the Active treatment will have a primary endpoint rate equal to or exceeding that of the usual care group. The alternative hypothesis is that the Active treatment will have the primary endpoint rate less than the usual care group rate. Specifically: Where is the true primary event rate for the Active treatment, is the true primary event rate for the usual care arm. The assumptions for this analysis are: -True primary event rate in the Active treatment group, is 24.5.0% -True primary event rate in the usual care treatment group, is 35.0% -Power is 90%. -Six (6) interim analyses will be conducted to evaluate both the superiority and futility followed by a final analysis -Superiority assessment will be assessed using the posterior probability of the alternative hypothesis as specified above, where = 0.95 -Futility assessment will be assessed using the posterior probability of the alternative hypothesis as specified above, where = 0.95 -Randomization will be carried out in an adaptive Bayesian fashion. The randomization ratio will be evaluated at each of the 6 interim analyses Rejection of the null hypothesis will signify that the Active treatment is superior to the usual care treatment with regards to primary endpoint event rates. A maximum total of 560 subjects, adaptively assigned to treatment A or C will have 86.3% power to reject the above null hypothesis in favor of the alternative under the stated assumptions. Since we are using the adaptive assignment and included the possibility of early stop for overwhelming futility or superiority, the groups sizes are a function of the data and therefore random. Under the alternative hypothesis, it is expected that at the time when the decision is made, the median group size will be 173 in treatment A and 113 in treatment C, thus, if treatment A is superior to treatment C, more participants will be treated with the more efficacious treatment. The one-sided type I error estimates are 9.3%. Additional operating characteristics of this design are presented in the shaded column of Table 1 , under the alternative hypothesis and under the null hypothesis). In Figure 1 , more detail on the operating characteristics of the design are presented. Under the alternative hypothesis. The cumulative probability of declaring the active treatment superior at different interim analyses, are displayed in the upper left panel. Similarly, the probability of declaring the usual care treatment superior (futility) at different interim analyses, are displayed in the upper right panel. In the lower left panel, the probability of randomizing a patient to the active treatment is displayed. In the lower right panel, the mean difference in sample size between the active and usual care arms are presented. Statistical analyses for the primary endpoint will be conducted using a statistical test for superiority of proportions based on posterior probability. Within each treatment group, a Beta (12,28) prior will be assumed for the true primary endpoint rate, and . This prior has a mean of 30% (average of assumed rates) was selected to express apriori skepticism of the alternative hypothesis being true; indeed, under this prior, the prior probability of the alternative hypothesis is 50%, while the probability of observing an improvement in the true rate of 10.5% or larger (the hypothesized improvement) is only 15%. Thus, a reversal in these prior skeptical stance will have to be only due to a strong support for the Active treatment in the data collected during the study. With this choice regarding the prior distribution, in each group, the posterior probability distribution of the primary event rates will be Beta(12+# of events, 28+#non-events). The criterion for success is based on the posterior probability of the alternative hypothesis (i.e., of superiority being met). The Active group will be declared superior to the usual care group if the posterior probability of the alternative hypothesis is large, that is Similarly, the Active group will be declared inferior to the usual care group if the posterior probability The thresholds, and are pre-specified levels of evidence we require to declare the alternative hypothesis true. The thresholds will be selected such that the overall type I rate for testing the primary hypothesis of superiority is bounded by 10%. A maximum of 6 interim looks will be scheduled after each 70 enrolled subjects enter the study and have finished follow-up. At this stage, the alternative hypothesis of superiority and the null hypothesis of inferiority will be evaluated. Our primary analysis will be a modified intention to treatment analysis where we will exclude participants after randomization who were transferred to the ICU (thus meeting primary outcome) before receiving their initial intervention or usual care text message. As participants in the usual care arm will be free to position themselves into the "prone" position, we will perform an additional secondary exploratory analysis comparing participants in the intervention arm reported lying "prone" for 6 or more hours on at least one survey to participants in the usual care arm who never report lying "prone" for 6 or more hours on all completed surveys. We will perform subgroup analyses for the primary outcome among the following groups of participants: 1) Receiving supplemental oxygen at the time of the initial intervention or usual care text message 2) Not receiving supplemental oxygen at the time of the initial intervention or usual care text message 3) Those with a positive COVID-19 test 4) Those with a negative or inconclusive COVID-19 test Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study Fair Allocation of Scarce Medical Resources in the Time of Covid-19 Prone Positioning in Severe Acute Respiratory Distress Syndrome Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label metatrial COVID-19 Practice Variations Across the USA and Beyond ICS Guidance for Prone Positioning of the Conscious COVID Patient Rationale and Design of the Awake Prone Position for Early Hypoxemia in COVID-19 (APPEX-19) Study Protocol The BUGS Book: A Practical Introduction to Bayesian Analysis The Effect of Smartphone App-Based Interventions for Patients With Hypertension: Systematic Review and Meta-Analysis Virtual Reality Smartphone-Based Intervention for Smoking Cessation: Pilot Randomized Controlled Trial on Initial Clinical Efficacy and Adherence Suite 800Washington, Inquiries D 20036USA202-419-4300 | M-857-8562 | F-419-4372 | M. Demographics of Mobile Device Ownership and Adoption in the United States [Internet]. Pew Research Center: Internet, Science & Tech Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support The REDCap consortium: Building an international community of software platform partners Psychophysical bases of perceived exertion The perception of breathlessness in asthma Effect of Prone Positioning on the Survival of Patients with Acute Respiratory Failure Awake-Prone Positioning Strategy for Non-Intubated Hypoxic Patients with COVID-19: A Pilot Trial with Embedded Implementation Evaluation Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials Prone positioning improves survival in severe ARDS: a pathophysiologic review and individual patient metaanalysis Dexamethasone in Hospitalized Patients with Covid-19 Those with BMIs at enrollment ≥30 Those with BMIs at enrollment <30 Those with opacities or infiltrates on their initial chest x-ray 8) Those without opacities or infiltrates on their initial chest x-ray Those with a history of congestive heart failure 10) Those without a history of congestive heart failure 11) Those aged ≥65 years 12) Those aged<65 years All authors assume responsibility for the overall content and integrity of this article. GR, AJW, SQS, GD, CSR, and NAB drafted he initial version of the manuscript and all members of the Details on the statistical methods for the secondary analyses will be provided in the Statistical Analysis Plan (SAP). This study is to be conducted according to applicable US federal regulations and institutional policies (which are based in federal regulations, guidance, and ICH Good Clinical Practice guidelines).This protocol and any amendments will be submitted to the Boston Medical Center and Boston University Medical Campus IRB, for formal approval of the study conduct. The decision of the IRB concerning the conduct of the study will be made in writing to the investigator.All subjects for this study will be provided a consent form describing this study and providing sufficient information for subjects to make an informed decision about their participation in this study. The consent form will be submitted with the protocol for review and approval by the IRB. The consent of a subject, using the IRB-approved consent form, must be obtained before that subject is submitted to any study procedure. Consent will be documented as required by the IRB.